Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Global Healthcare ETF (NY:IXJ)

83.57 +0.51 (+0.61%)
Official Closing Price Updated: 4:10 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Global Healthcare ETF

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Trump Overrode RFK Jr. And Makary To Remove FDA Biologics Chief Amid Sarepta Drug Controversy: Report
The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics. 
Via Stocktwits
Topics Death ETFs Government
RFK Jr. Said To Be Planning Another Health Panel Shakeup — This Time Targeting Preventive Care
Via Stocktwits
Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)
In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at... 
Via MarketMinute
Topics ETFs Economy
Global Healthcare ETFs
Trevor Cummings discusses Global Healthcare ETFs and outlook for the rest of 2021 with Deborah Fuhr. 
Via Talk Markets
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens
The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025. 
Via Stocktwits
J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient
During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually. 
Via Stocktwits
Topics Earnings
World Health Organization Responds to Trump's Order, Reminds Decades of Successful Health Achievements
Trump signs an order to withdraw the U.S. from WHO, citing pandemic mismanagement, political influence, and inequitable funding, reigniting a past debate. 
Via Benzinga
Topics Government
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide. 
Via MarketBeat
Topics ETFs
Want to Earn More in the Stock Market With Less Effort? Try This Simple Strategy
You don't need to be a stock market expert to earn above-average returns. 
Via The Motley Fool
Top ETFs for Every Sector
Top ETFs for all 11 S&P 500 sectors. 
Via The Motley Fool
Topics ETFs Stocks
Market Mayhem: 3 ETFs to Anchor Your Investments in 2024
The top ETFs for 2024 are thematic or sector-specific tickers with upside, presenting market-beating opportunities. 
Via InvestorPlace
Topics ETFs
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
3 Healthcare Technology Stocks to Improve Lives in 2024
Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks. 
Via InvestorPlace
Worried About a Recession? Stash Your Cash in These 2 ETFs.
Rather than holding your cash, consider investing it in these stable ETFs. 
Via The Motley Fool
US Supports Delay On COVID Patent Waiver Extension Decision
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health... 
Via Benzinga
7 Profitable Places to Hide Your Money During a Bear Market
With an imminent bear market on the horizon, investors are searching for alternative investment paths for diversification. 
Via InvestorPlace
Why WHO Did Not Recommend Convalescent Plasma Therapy For COVID-19
The World Health Organization said that it's not recommending the use of convalescent plasma as a treatment for COVID-19 for mild or severe cases. The treatment uses... 
Via Benzinga
New Drug Applications Pile Up With FDA As Pandemic Still Sore Spot For Delayed Inspections
The FDA continues to face a backlog of drug manufacturing facility inspections. A total of 52 new drug (but no biologics) applications remain delayed due to the backlog... 
Via Benzinga
UK Rolls Out COVID-19 Antibody Tests For All: What You Need To Know
On Sunday, the U.K. government rolled out a new nationwide antibody surveillance program, in which anyone over 18 years can opt-in when having a PCR test from Tuesday.... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.